Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence
Miller C, Althoff K, Schlueter D, Anton-Culver H, Chen Q, Garbett S, Ratsimbazafy F, Thomsen I, Karlson E, Cicek M, Pinto L, Malin B, Ohno-Machado L, Williams C, Goldstein D, Kouame A, Ramirez A, Gebo K, Schully S. Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence. MSphere 2022, 7: e00257-22. PMID: 36173112, PMCID: PMC9599436, DOI: 10.1128/msphere.00257-22.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralCOVID-19HumansImmunoglobulin GPopulation HealthPrevalenceSARS-CoV-2Sensitivity and SpecificitySeroepidemiologic StudiesConceptsSARS-CoV-2 antibody concentrationsLow prevalenceVaccine availabilitySARS-CoV-2 enzyme-linked immunosorbent assayFalse positivityLow SARS-CoV-2 prevalenceSARS-CoV-2 IgG assaysSARS-CoV-2 IgG testSARS-CoV-2 IgG antibodiesSevere acute respiratory syndrome coronavirus 2Coronavirus disease 2019 prevalenceAcute respiratory syndrome coronavirus 2Antibody concentrationsSARS-CoV-2 testDifferent antigensRespiratory syndrome coronavirus 2SARS-CoV-2 prevalenceSyndrome coronavirus 2SARS-CoV-2 pandemicConcordant positive resultsConcordant negative resultsEnzyme-linked immunosorbent assayPositive resultsFuture pandemic preparednessConcordance of results